Valneva SE (VALN) Non-Current Deferred Tax Liability (2019 - 2026)
Valneva SE (VALN) posted quarterly Non-Current Deferred Tax Liability of $5.0 million for Q1 2026, up 7.21% year-on-year from $4.7 million in Q1 2025, and little changed on a QoQ basis from $5.0 million in Q4 2025.
Valneva SE (VALN) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Non-Current Deferred Tax Liability for 8 consecutive years, with $5.0 million the latest figure, recorded in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 7.21% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 7.21% YoY) and the FY2025 annual result came in at $5.0 million, up 5.93% from the prior year.
- Non-Current Deferred Tax Liability was little changed at $5.0 million in Q1 2026 per VALN's latest filing, from $5.0 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for VALN reached as high as $14.8 million in Q4 2023 and fell as low as $789740.3 in Q4 2022.
- A 5-year average of $4.0 million and a median of $4.3 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability soared 1768.44% — and 2024, when it tumbled 67.9%.
- Year by year, Non-Current Deferred Tax Liability stood at $789740.3 in 2022, then surged by 1768.44% to $14.8 million in 2023, then tumbled by 67.9% to $4.7 million in 2024, then climbed by 5.93% to $5.0 million in 2025, then rose by 0.48% to $5.0 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $5.0 million, $5.0 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.04 Mn |
| Mar 31, 2026 | 5.04 Mn |
| Dec 31, 2025 | 5.02 Mn |
| Dec 31, 2025 | 5.02 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Jun 30, 2025 | 4.59 Mn |
| Jun 30, 2025 | 4.59 Mn |
| Mar 31, 2025 | 4.70 Mn |
| Mar 31, 2025 | 4.70 Mn |
| Dec 31, 2024 | 4.74 Mn |
| Dec 31, 2024 | 4.74 Mn |
| Sep 30, 2024 | 4.31 Mn |
| Sep 30, 2024 | 4.31 Mn |
| Jun 30, 2024 | 4.26 Mn |
| Jun 30, 2024 | 4.26 Mn |
| Mar 31, 2024 | 4.21 Mn |
| Mar 31, 2024 | 4.21 Mn |
| Dec 31, 2023 | 14.76 Mn |
| Dec 31, 2023 | 14.76 Mn |